In a significant development, biotech player, Noxopharm Limited (ASX:NOX) has announced commencement of its NOXCOVID clinical program in Europe while discussions with FDA continues.
Noxopharm is continuing NOXCOVID program in two parallel paths:
- Commencement of Phase 1 study (NOXCOVID-1) in COVID-19 patients in Europe to provide crucial safety data and proof-of-principle of Veyonda® in a cost-effective and timely way before committing to a significantly larger study.
- Progressing discussions with FDA towards obtaining IND (Investigational New Drug) approval for an expanded clinical trial in USA.
As at 12:16 PM AEST, NOX is trading at $0.195, with a rise of ~2.6 per cent.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.